Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

ImmusanT Releases Phase I Clinical Trial Results for Celiac Therapeutic

XTALKS VITALS NEWS

Wheat

Celiac disease is a chronic immune-modulated disease in which exposure to dietary gluten causes damage to the gastrointestinal lining.

Share this!

February 24, 2017 | by Sarah Hand, M.Sc.

Massachusetts-based biotech company ImmusanT, has completed a Phase Ib clinical trial for its celiac disease vaccine, Nexvax2. The therapeutic – which is designed to protect against the effects of gluten exposure – met its objectives in terms of safety and efficacy.

Celiac disease is a chronic immune-modulated disease in which exposure to dietary gluten causes damage to the gastrointestinal lining. Aside from dietary restriction, there is no pharmacological treatment for this disease which effects an estimated one percent of the population in the US.

Approximately 90 percent of patients carry the human leukocyte antigen-DQ2.5 (HLA-DQ2.5) immune recognition gene, which has been implicated in the genetic basis of the condition. ImmusanT’s Nexvax2 is an immunotherapy consisting of three peptides designed to promote gluten tolerance in the intestine.

The Phase Ib dose titration clinical trial involved 38 patients with celiac disease who were randomly assigned to one of three cohorts based upon HLA-DQ2.5 genotype. Patients received either escalating doses of Nexvax2, or a placebo, and study results will help inform a dosing regimen for a further Phase II trial.



Previous study results found that while patients given a fixed dose of Nexvax2 initially experienced transient immune activation and symptoms associated with gluten consumption, future doses did not trigger an immune response. No safety concerns were identified during the current clinical trial.

“We are very pleased with the completion of our Phase 1b clinical trial testing Nexvax2 in patients with HLA-DQ2.5+ celiac disease,” said Leslie Williams, President and Chief Executive Officer of ImmusanT. “This study has informed the design of our planned Phase 2 clinical trial for Nexvax2 in patients with celiac disease. Nexvax2 has the potential to protect against the effects of gluten exposure in patients with celiac disease and improve their quality of life.”

Should future trials show similarly promising results, ImmusanT will likely seek US Food and Drug Administration (FDA) approval for Nexvax2 as a therapeutic to protect celiac patients who are accidently exposed to gluten. The company is also developing a companion diagnostic and monitoring tool to help identify those who may benefit from ImmusanT.

It’s estimated that over 80 percent of cases of celiac disease are undiagnosed in the US. While a gluten-free diet is imperative for disease management, adherence can be difficult leaving patients open to further intestinal damage flowing exposure to gluten.


Keywords: Clinical Trial, Immunotherapy, Celiac Disease


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Lavazza Acquires Controlling Stake in Canada’s Kicking Horse Coffee

May 26, 2017 - Italian coffee company Lavazza, has secured an 80 percent equity stake in Canadian organic and fair-trade coffee company Kicking Horse Coffee, in a deal worth CAD$215 million.

Featured In: Food News


FDA First: Keytruda Approved for Cancer Treatment Based on Biomarker Alone

May 25, 2017 - For the first time, the FDA has approved a cancer treatment for solid tumors based on the presence of a biomarker, as opposed to specifying a tissue of origin.

Featured In: Biotech News


One Year of Medically Assisted Dying in Canada

May 25, 2017 - In June of 2016, the federal government of Canada passed legislation to legalize medically assisted dying.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Life Sciences During the Last Week

REGISTER FOR THESE WEBINARS

EU IVD Regulation: Top Five Changes for Medical Device Manufacturers to Consider


Thermal Processing Systems for the Food Industry: A Guide to Selecting Thermal Equipment and Technology


Rare Disease & Orphan Drug Development: Cost-Efficient Trial Design to Minimize Cash Burn


eTMF Workflows: Active eTMF to Improve the Quality of Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.